Literature DB >> 2117516

Ovarian function during use of a levonorgestrel-releasing IUD.

I Barbosa1, O Bakos, S E Olsson, V Odlind, E D Johansson.   

Abstract

Ovarian function was studied for two complete menstrual cycles in 9 regularly menstruating women and for 8 weeks in three amenorrhoeic women who had used levonorgestrel-releasing IUDs (LNG-IUD) for more than four years. Nine patients using copper IUDs (Nova-T) were studied for two complete menstrual cycles as controls. According to progesterone levels, 15/17 cycles in women using LNG-IUDs were ovulatory, whereas only 8/17 cycles showed normal follicular growth and rupture as judged by ultrasound. In ovulatory cycles, the peak progesterone levels were lower than in the controls. The preovulatory estradiol and LH peak levels were also lower than in control subjects. SHBG levels were lower in LNG-IUD users than in copper IUD users. It is concluded that, although the dose of levonorgestrel released from the IUD is very low, it probably exerts an effect on the gonadotrophin secretion, which disturbs follicular development in many of the women studied, which in addition to the local effect on the endometrium, contributes to its high contraceptive efficacy.

Entities:  

Keywords:  Biology; Cervical Mucus--analysis; Cervix; Contraception; Contraceptive Agents, Female--analysis; Contraceptive Agents, Progestin--analysis; Contraceptive Agents--analysis; Contraceptive Methods; Control Groups; Endocrine System; Estradiol--analysis; Estrogens; Examinations And Diagnoses; Family Planning; Follicle Stimulating Hormone--analysis; Genitalia; Genitalia, Female; Germ Cells; Gonadotropins; Gonadotropins, Pituitary; Hormones; Iud; Iud, Copper Releasing; Iud, Hormone Releasing; Laboratory Examinations And Diagnoses; Levonorgestrel--analysis; Luteinizing Hormone--analysis; Ovarian Effects; Ovary; Physiology; Research Methodology; Spermatozoa--analysis; Ultrasonics; Urogenital System; Uterus

Mesh:

Substances:

Year:  1990        PMID: 2117516     DOI: 10.1016/0010-7824(90)90092-a

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  8 in total

1.  Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding.

Authors:  P Warner; A Guttinger; A F Glasier; R J Lee; S Nickerson; R M Brenner; H O D Critchley
Journal:  Hum Reprod       Date:  2009-11-07       Impact factor: 6.918

Review 2.  A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.

Authors:  F Sturridge; J Guillebaud
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

3.  Impact of Combined Hormonal Contraceptive Use on Weight Loss: A Secondary Analysis of a Behavioral Weight-Loss Trial.

Authors:  Ann E Caldwell; Adnin Zaman; Danielle M Ostendorf; Zhaoxing Pan; Bryan B Swanson; Suzanne Phelan; Holly R Wyatt; Daniel H Bessesen; Edward L Melanson; Victoria A Catenacci
Journal:  Obesity (Silver Spring)       Date:  2020-06       Impact factor: 5.002

4.  Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.

Authors:  Tiina Backman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 5.  Levonorgestrel. Clinical pharmacokinetics.

Authors:  K Fotherby
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

6.  Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS.

Authors:  Paula H Bednarek; Jeffrey T Jensen
Journal:  Int J Womens Health       Date:  2010-08-09

Review 7.  Induction and Maintenance of Amenorrhea in Transmasculine and Nonbinary Adolescents.

Authors:  Jeremi M Carswell; Stephanie A Roberts
Journal:  Transgend Health       Date:  2017-11-01

8.  A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo.

Authors:  Guillermo Villegas; Giulia Calenda; Shweta Ugaonkar; Shimin Zhang; Larisa Kizima; Olga Mizenina; Agegnehu Gettie; James Blanchard; Michael L Cooney; Melissa Robbiani; José A Fernández-Romero; Thomas M Zydowsky; Natalia Teleshova
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.